Condition

Nonsmall Cell Lung Cancer

ClinicalTrials.gov condition label

Clinical trials59
Recruiting7
Common interventions25
Lead sponsors shown15

Clinical trials

59 shown
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsNCT07636785 · 2026-07-16
RECRUITING
Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLCNCT07626736 · 2025-12-01
RECRUITING
Patient-centered, Optimal Integration of Survivorship and Palliative CareNCT04900935 · 2023-09-29
RECRUITING
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerNCT06147570 · 2023-09-25
RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsNCT05283330 · 2022-12-22
RECRUITING
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyNCT04253964 · 2020-07-01
RECRUITING
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid TumorsNCT03778814 · 2018-12-01
RECRUITING
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNCT05275374 · 2025-12-31
NOT_YET_RECRUITING
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLCNCT05873439 · 2023-05-25
COMPLETED
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentNCT04625699 · 2022-12-01
WITHDRAWN
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STSNCT05688280 · 2022-11-29
ACTIVE_NOT_RECRUITING
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24
ACTIVE_NOT_RECRUITING
A Study of [14C]GB491 in Male Healthy SubjectsNCT05860582 · 2022-09-14
COMPLETED
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsNCT05082610 · 2022-02-28
COMPLETED
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient PopulationNCT05863052 · 2022-01-31
ACTIVE_NOT_RECRUITING
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCNCT04984811 · 2021-11-15
TERMINATED
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2bNCT04396340 · 2020-05-11
TERMINATED
Metabolic and Microbial Profiling of Lung CancerNCT03998189 · 2019-10-11
TERMINATED
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLCNCT03769805 · 2019-06-15
UNKNOWN
Study of Lorlatinib in ROS1 Rearranged NSCLCNCT03612154 · 2019-05-02
UNKNOWN
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesNCT03753685 · 2019-04-12
ACTIVE_NOT_RECRUITING
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor HistologyNCT03940846 · 2019-03-01
UNKNOWN
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLCNCT02905591 · 2018-11-16
ACTIVE_NOT_RECRUITING
The Tracking Molecular Evolution for NSCLC (T-MENC) StudyNCT03838588 · 2018-11-06
UNKNOWN
A Mobile Supportive Care App for Patients With Metastatic Lung CancerNCT03512015 · 2018-05-15
UNKNOWN
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerNCT03450330 · 2018-04-16
COMPLETED
Study of Nivolumab for Advanced Cancers in IndiaNCT03444766 · 2018-03-06
COMPLETED
IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung CancerNCT03258671 · 2017-10-01
UNKNOWN
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLCNCT03256721 · 2017-08-16
TERMINATED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · 2017-05-29
COMPLETED
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCNCT02981108 · 2017-05-08
UNKNOWN
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung CancerNCT02963610 · 2017-03-29
TERMINATED
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLCNCT02988141 · 2017-03-01
UNKNOWN
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLCNCT03044626 · 2017-02-10
COMPLETED
Atezolizumab as Induction Therapy in Non-small Cell Lung CancerNCT02994576 · 2016-12-12
COMPLETED
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerNCT02967133 · 2016-12-01
TERMINATED
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MNCT02972333 · 2016-12-01
UNKNOWN
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismNCT03002844 · 2016-12-01
UNKNOWN
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NCT02973789 · 2016-12-01
COMPLETED
Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung CancerNCT02974933 · 2016-11-01
UNKNOWN
cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia ChinaNCT02980536 · 2016-11-01
UNKNOWN
Effects of Acupuncture Stimulation on Systemic InflammationNCT02951611 · 2016-11-01
UNKNOWN
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsNCT02954523 · 2016-10-01
TERMINATED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsNCT02669914 · 2016-09-12
TERMINATED
Skeletal Muscle Atrophy and Dysfunction in Human CancerNCT02949076 · 2016-07-01
COMPLETED
Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)NCT02419170 · 2016-07-01
WITHDRAWN
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerNCT03050411 · 2016-05-01
UNKNOWN
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)NCT02705339 · 2016-05-01
WITHDRAWN
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsNCT02537561 · 2015-12-01
WITHDRAWN
SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung CancerNCT02562027 · 2015-09-11
COMPLETED
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)NCT02342353 · 2015-05-18
TERMINATED
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerNCT02299141 · 2015-05-07
COMPLETED
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease ProgressionNCT02431169 · 2015-04-30
TERMINATED
Pazopanib in Molecularly Selected Patients With Advanced NSCLCNCT02193152 · 2015-04-27
TERMINATED
Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyNCT02972216 · 2014-11-01
COMPLETED
Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC PatientsNCT02010047 · 2013-12-01
COMPLETED
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung CancerNCT01999673 · 2013-12-01
COMPLETED
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)NCT01312337 · 2010-09-01
UNKNOWN
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain MetastasisNCT01301560 · 2008-06-01
UNKNOWN

Common interventions

CisplatinDRUG4AtezolizumabDRUG3CarboplatinDRUG3NivolumabDRUG3PaclitaxelDRUG3PembrolizumabDRUG3EGFR-TK InhibitorDRUG2GemcitabineDRUG2PemetrexedDRUG2trametinibDRUG2[14C]GB491DRUG11.0% IP-001 for InjectionDRUG1²¹²Pb-DOTAM-GRPR1DRUG1Acupuncture stimulationPROCEDURE1ALK qPCR assayDEVICE1AnlotinibDRUG1Apatinib combined with pemetrexedDRUG1Apatinib Mesylate TabletsDRUG1Apatinib/docetaxel/pemetrexedDRUG1ApheresisPROCEDURE1Ascorbic AcidDRUG1AZD4205DRUG1AZD9291 80mg oral each dayDRUG1bavituximabBIOLOGICAL1BiopsyPROCEDURE1

Trial status mix

UNKNOWN16
COMPLETED15
TERMINATED11
RECRUITING7
ACTIVE_NOT_RECRUITING5
WITHDRAWN4
NOT_YET_RECRUITING1

Phase mix

PHASE226
PHASE116
NA10
PHASE35
EARLY_PHASE12
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.